Country Access Report
Egypt maintains a highly restrictive national drug control regime with criminal penalties for unauthorized possession or use of narcotics and psychotropic substances; however, ketamine is an established, controlled medicinal anesthetic and is used in Egyptian hospitals and research settings. Other classic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) have no authorized medical market access outside approved clinical research and remain controlled under Egypt's narcotics/psychotropic laws.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Egypt's narcotics and psychotropic substance regime criminalizes possession, use and trafficking of unauthorised narcotics and psychotropic substances and provides no routine medical/insured pathway for psilocybin-based treatments. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no publicly available regulatory pathway, national approval, or reimbursement mechanism in Egypt for MDMA‑assisted therapy; possession or trafficking can attract criminal sanctions under Egypt's anti‑narcotics legislation. [1] [2]
Compound Access
Esketamine (Spravato) does not appear to have an established national market authorization or publicly documented Ministry of Health reimbursement pathway in Egypt as of available sources searched through February 20, 2026; there is no publicly discoverable Egyptian MOH product registration listing or government reimbursement policy for esketamine analogous to Spravato's approvals in other jurisdictions. Consequently, routine insured reimbursement and a national REMS‑style supervised outpatient program are not in evidence for esketamine in Egypt; any access would likely require individual import authorisation or use in formal clinical research and would be exceptional. For contrast, esketamine/Spravato has defined REMS/administration requirements in jurisdictions where it is approved (example: US FDA approval history). [1] [2]
Compound Access
Ketamine is an established, registered medicinal product in Egypt used in anesthesia, emergency and some research/clinical settings; it is a controlled prescription medicine distributed for hospital use and is documented in Egyptian pharmaceutical product listings and local clinical literature. Domestic product listings indicate ketamine formulations registered for human use with controlled distribution, and Egyptian clinical journals and clinical‑trial registries show ketamine's use in anesthesia, perioperative analgesia and research projects conducted in Egyptian hospitals and universities. Access pathway: prescription for legitimate medical indications (primarily anesthesia, analgesia, sedation); distribution is controlled and typically limited to hospital pharmacies or authorised clinical settings, with no evidence of routine public‑payer reimbursement for off‑label psychiatric uses (e.g., depression) as a nationally funded mental‑health therapy program. Regional/state variation: Egypt operates a centralized national regulatory and health system; prescribing and distribution controls are implemented at national and institutional levels (Ministry of Health / hospital pharmacy governance). Key sources: national product listing entries indicating Ketamine registration for hospital use [1]; examples of Egyptian clinical research and published anesthesia literature demonstrating in‑country use of ketamine in hospitals and clinical studies. [2] [3]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no established clinical or reimbursement pathway for DMT in Egypt and possession/use outside authorised research is criminalized. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No legal medical/reimbursement pathway exists in Egypt for 5‑MeO‑DMT. Unauthorized possession or supply is subject to criminal penalties. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Egypt has no established ibogaine treatment programs or reimbursement mechanisms; any use would be limited to approved research contexts (if permitted) and otherwise is criminalized. [1] [2]
Compound Access
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no national programs or reimbursement pathways for mescaline or mescaline‑containing cacti when used as hallucinogens. Unauthorized possession, production or trafficking is subject to criminal penalties. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel psychoactive substituted phenethylamines (2C family) are covered by Egypt's broad controls on psychotropic substances and often encompassed by legislation addressing new/novel psychoactive substances; there is no medical/reimbursement pathway. [1] [2]
Last updated 2 Mar 2026. Source links come from the medical access guide.